Physician profile
James M Link
NPI 1629061056
$1,601.33
in general payments reported to CMS, 2019-2025
25 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.85 · 2020: $150 · 2021: $36.98 · 2022: $110 · 2023: $337 · 2024: $661 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,273.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $248.12 | 2023-2025 | Veozah, Myrbetriq |
| Gynesonics, INC. | $185.95 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Baxter Healthcare | $157.50 | 2024 | Tisseel |
| Hologic Sales and Service, LLC | $139.69 | 2022-2025 | Novasure, Acessa Provu System, Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $111.51 | 2020-2023 | |
| Organon LLC | $78.25 | 2024-2025 | Nexplanon |
| Biogen, INC. | $70.58 | 2025 | Zurzuvae |
| Avion Pharmaceuticals | $70.56 | 2020-2023 | Balcoltra |
| Pfizer INC. | $66.32 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $63.30 | 2023-2025 | |
| Abbvie INC. | $61.17 | 2020-2023 | |
| Exact Sciences Corporation | $58.34 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $41.32 | 2023-2024 | Gardasil 9, Gardasil |
| Sumitomo Pharma America, INC. | $39.60 | 2024-2025 | Myfembree |
| Alpha Orthopedic Systems | $36.86 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $32.36 | 2023 | Ova1 |
| Medicem INC. | $19.48 | 2022 | |
| Coopersurgical, INC. | $18.74 | 2023 | Paragard T 380a |
| Daiichi Sankyo INC. | $17.67 | 2019 | |
| Kerecis Limited | $16.34 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Agile Therapeutics, INC. | $15.57 | 2023 | Twirla |
| Sanofi Pasteur INC. | $13.61 | 2025 | |
| Radius Health, INC. | $13.46 | 2024 | Tymlos |
| Exeltis, USA INC. | $13.13 | 2024 | Slynd |
| Evofem Biosciences, INC. | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Link listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.